Intrinsic value of Chemours - CC

Previous Close

$46.08

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

  Value-price divergence*

-488%

Previous close

$46.08

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

 
Value-price divergence*

-488%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of CC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 8.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -5.54
  10.80
  10.22
  9.70
  9.23
  8.81
  8.42
  8.08
  7.77
  7.50
  7.25
  7.02
  6.82
  6.64
  6.47
  6.33
  6.19
  6.07
  5.97
  5.87
  5.78
  5.71
  5.63
  5.57
  5.51
  5.46
  5.42
  5.37
  5.34
  5.30
  5.27
Revenue, $m
  5,400
  5,983
  6,595
  7,234
  7,902
  8,598
  9,322
  10,075
  10,859
  11,673
  12,519
  13,398
  14,311
  15,261
  16,250
  17,278
  18,348
  19,462
  20,624
  21,835
  23,097
  24,415
  25,791
  27,228
  28,729
  30,298
  31,939
  33,656
  35,452
  37,333
  39,301
Variable operating expenses, $m
 
  6,119
  6,743
  7,395
  8,076
  8,786
  9,525
  10,294
  11,093
  11,923
  12,786
  13,668
  14,600
  15,569
  16,577
  17,626
  18,718
  19,855
  21,040
  22,275
  23,563
  24,907
  26,311
  27,777
  29,308
  30,909
  32,583
  34,335
  36,167
  38,085
  40,094
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  5,474
  6,119
  6,743
  7,395
  8,076
  8,786
  9,525
  10,294
  11,093
  11,923
  12,786
  13,668
  14,600
  15,569
  16,577
  17,626
  18,718
  19,855
  21,040
  22,275
  23,563
  24,907
  26,311
  27,777
  29,308
  30,909
  32,583
  34,335
  36,167
  38,085
  40,094
Operating income, $m
  -74
  -136
  -148
  -161
  -175
  -189
  -203
  -218
  -234
  -251
  -268
  -270
  -289
  -308
  -328
  -348
  -370
  -392
  -416
  -440
  -466
  -492
  -520
  -549
  -579
  -611
  -644
  -679
  -715
  -753
  -793
EBITDA, $m
  210
  178
  196
  215
  235
  256
  277
  300
  323
  347
  372
  398
  426
  454
  483
  514
  546
  579
  613
  649
  687
  726
  767
  810
  854
  901
  950
  1,001
  1,054
  1,110
  1,169
Interest expense (income), $m
  208
  195
  200
  233
  269
  306
  345
  385
  427
  470
  516
  563
  611
  662
  715
  770
  827
  886
  948
  1,013
  1,080
  1,150
  1,224
  1,300
  1,380
  1,463
  1,550
  1,642
  1,737
  1,837
  1,941
Earnings before tax, $m
  -11
  -331
  -348
  -395
  -444
  -495
  -548
  -603
  -661
  -721
  -783
  -833
  -900
  -970
  -1,043
  -1,118
  -1,197
  -1,279
  -1,364
  -1,453
  -1,546
  -1,643
  -1,744
  -1,849
  -1,959
  -2,074
  -2,194
  -2,320
  -2,452
  -2,590
  -2,734
Tax expense, $m
  -18
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  7
  -331
  -348
  -395
  -444
  -495
  -548
  -603
  -661
  -721
  -783
  -833
  -900
  -970
  -1,043
  -1,118
  -1,197
  -1,279
  -1,364
  -1,453
  -1,546
  -1,643
  -1,744
  -1,849
  -1,959
  -2,074
  -2,194
  -2,320
  -2,452
  -2,590
  -2,734

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  902
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  6,060
  6,715
  7,401
  8,119
  8,868
  9,649
  10,462
  11,308
  12,187
  13,101
  14,050
  15,037
  16,062
  17,128
  18,237
  19,391
  20,592
  21,843
  23,147
  24,506
  25,923
  27,402
  28,946
  30,558
  32,243
  34,005
  35,847
  37,773
  39,789
  41,900
  44,109
Adjusted assets (=assets-cash), $m
  5,158
  6,715
  7,401
  8,119
  8,868
  9,649
  10,462
  11,308
  12,187
  13,101
  14,050
  15,037
  16,062
  17,128
  18,237
  19,391
  20,592
  21,843
  23,147
  24,506
  25,923
  27,402
  28,946
  30,558
  32,243
  34,005
  35,847
  37,773
  39,789
  41,900
  44,109
Revenue / Adjusted assets
  1.047
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
  0.891
Average production assets, $m
  2,994
  3,315
  3,653
  4,008
  4,378
  4,763
  5,164
  5,582
  6,016
  6,467
  6,935
  7,422
  7,929
  8,455
  9,002
  9,572
  10,165
  10,782
  11,426
  12,096
  12,796
  13,526
  14,288
  15,084
  15,916
  16,785
  17,694
  18,645
  19,641
  20,682
  21,773
Working capital, $m
  782
  -114
  -125
  -137
  -150
  -163
  -177
  -191
  -206
  -222
  -238
  -255
  -272
  -290
  -309
  -328
  -349
  -370
  -392
  -415
  -439
  -464
  -490
  -517
  -546
  -576
  -607
  -639
  -674
  -709
  -747
Total debt, $m
  3,544
  3,628
  4,245
  4,891
  5,566
  6,268
  7,000
  7,761
  8,552
  9,375
  10,229
  11,117
  12,040
  13,000
  13,998
  15,036
  16,117
  17,243
  18,416
  19,639
  20,915
  22,246
  23,635
  25,087
  26,603
  28,188
  29,846
  31,580
  33,394
  35,294
  37,282
Total liabilities, $m
  5,960
  6,044
  6,661
  7,307
  7,982
  8,684
  9,416
  10,177
  10,968
  11,791
  12,645
  13,533
  14,456
  15,416
  16,414
  17,452
  18,533
  19,659
  20,832
  22,055
  23,331
  24,662
  26,051
  27,503
  29,019
  30,604
  32,262
  33,996
  35,810
  37,710
  39,698
Total equity, $m
  100
  672
  740
  812
  887
  965
  1,046
  1,131
  1,219
  1,310
  1,405
  1,504
  1,606
  1,713
  1,824
  1,939
  2,059
  2,184
  2,315
  2,451
  2,592
  2,740
  2,895
  3,056
  3,224
  3,400
  3,585
  3,777
  3,979
  4,190
  4,411
Total liabilities and equity, $m
  6,060
  6,716
  7,401
  8,119
  8,869
  9,649
  10,462
  11,308
  12,187
  13,101
  14,050
  15,037
  16,062
  17,129
  18,238
  19,391
  20,592
  21,843
  23,147
  24,506
  25,923
  27,402
  28,946
  30,559
  32,243
  34,004
  35,847
  37,773
  39,789
  41,900
  44,109
Debt-to-equity ratio
  35.440
  5.400
  5.740
  6.020
  6.280
  6.500
  6.690
  6.860
  7.020
  7.160
  7.280
  7.390
  7.500
  7.590
  7.680
  7.750
  7.830
  7.890
  7.960
  8.010
  8.070
  8.120
  8.170
  8.210
  8.250
  8.290
  8.330
  8.360
  8.390
  8.420
  8.450
Adjusted equity ratio
  -0.155
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  7
  -331
  -348
  -395
  -444
  -495
  -548
  -603
  -661
  -721
  -783
  -833
  -900
  -970
  -1,043
  -1,118
  -1,197
  -1,279
  -1,364
  -1,453
  -1,546
  -1,643
  -1,744
  -1,849
  -1,959
  -2,074
  -2,194
  -2,320
  -2,452
  -2,590
  -2,734
Depreciation, amort., depletion, $m
  284
  314
  344
  376
  410
  444
  481
  518
  557
  598
  640
  669
  714
  762
  811
  862
  916
  971
  1,029
  1,090
  1,153
  1,219
  1,287
  1,359
  1,434
  1,512
  1,594
  1,680
  1,769
  1,863
  1,962
Funds from operations, $m
  1,078
  -17
  -3
  -18
  -34
  -50
  -68
  -85
  -104
  -123
  -143
  -164
  -186
  -208
  -232
  -256
  -281
  -308
  -335
  -363
  -393
  -424
  -456
  -490
  -525
  -562
  -600
  -640
  -682
  -726
  -772
Change in working capital, $m
  484
  -11
  -12
  -12
  -13
  -13
  -14
  -14
  -15
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -36
  -37
Cash from operations, $m
  594
  -6
  8
  -6
  -21
  -37
  -54
  -71
  -89
  -108
  -127
  -147
  -168
  -190
  -213
  -236
  -261
  -286
  -313
  -340
  -369
  -399
  -430
  -463
  -497
  -532
  -569
  -608
  -648
  -691
  -735
Maintenance CAPEX, $m
  0
  -270
  -299
  -329
  -361
  -394
  -429
  -465
  -503
  -542
  -583
  -625
  -669
  -714
  -762
  -811
  -862
  -916
  -971
  -1,029
  -1,090
  -1,153
  -1,219
  -1,287
  -1,359
  -1,434
  -1,512
  -1,594
  -1,680
  -1,769
  -1,863
New CAPEX, $m
  -338
  -321
  -339
  -354
  -370
  -385
  -401
  -417
  -434
  -451
  -469
  -487
  -506
  -526
  -547
  -570
  -593
  -617
  -643
  -671
  -700
  -730
  -762
  -796
  -832
  -869
  -909
  -951
  -995
  -1,042
  -1,091
Cash from investing activities, $m
  357
  -591
  -638
  -683
  -731
  -779
  -830
  -882
  -937
  -993
  -1,052
  -1,112
  -1,175
  -1,240
  -1,309
  -1,381
  -1,455
  -1,533
  -1,614
  -1,700
  -1,790
  -1,883
  -1,981
  -2,083
  -2,191
  -2,303
  -2,421
  -2,545
  -2,675
  -2,811
  -2,954
Free cash flow, $m
  951
  -596
  -629
  -690
  -752
  -817
  -884
  -954
  -1,026
  -1,101
  -1,178
  -1,259
  -1,343
  -1,431
  -1,522
  -1,617
  -1,716
  -1,820
  -1,928
  -2,041
  -2,159
  -2,282
  -2,411
  -2,546
  -2,687
  -2,835
  -2,991
  -3,153
  -3,323
  -3,502
  -3,689
Issuance/(repayment) of debt, $m
  -381
  84
  618
  646
  674
  703
  732
  761
  791
  822
  854
  888
  923
  960
  998
  1,038
  1,081
  1,126
  1,173
  1,223
  1,276
  1,331
  1,390
  1,451
  1,517
  1,585
  1,658
  1,734
  1,814
  1,899
  1,989
Issuance/(repurchase) of shares, $m
  11
  902
  416
  466
  519
  573
  629
  688
  749
  812
  878
  931
  1,003
  1,077
  1,154
  1,234
  1,317
  1,404
  1,495
  1,589
  1,688
  1,791
  1,898
  2,010
  2,128
  2,250
  2,379
  2,513
  2,653
  2,801
  2,955
Cash from financing (excl. dividends), $m  
  -374
  986
  1,034
  1,112
  1,193
  1,276
  1,361
  1,449
  1,540
  1,634
  1,732
  1,819
  1,926
  2,037
  2,152
  2,272
  2,398
  2,530
  2,668
  2,812
  2,964
  3,122
  3,288
  3,461
  3,645
  3,835
  4,037
  4,247
  4,467
  4,700
  4,944
Total cash flow (excl. dividends), $m
  558
  390
  405
  423
  441
  459
  477
  495
  514
  534
  554
  560
  582
  605
  630
  655
  682
  710
  740
  772
  805
  840
  877
  916
  957
  1,000
  1,046
  1,094
  1,145
  1,198
  1,254
Retained Cash Flow (-), $m
  26
  -902
  -416
  -466
  -519
  -573
  -629
  -688
  -749
  -812
  -878
  -931
  -1,003
  -1,077
  -1,154
  -1,234
  -1,317
  -1,404
  -1,495
  -1,589
  -1,688
  -1,791
  -1,898
  -2,010
  -2,128
  -2,250
  -2,379
  -2,513
  -2,653
  -2,801
  -2,955
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -513
  -11
  -44
  -78
  -114
  -152
  -193
  -235
  -278
  -324
  -371
  -420
  -471
  -524
  -579
  -635
  -694
  -755
  -818
  -883
  -951
  -1,021
  -1,095
  -1,171
  -1,250
  -1,333
  -1,419
  -1,509
  -1,602
  -1,700
Discount rate, %
 
  11.80
  12.39
  13.01
  13.66
  14.34
  15.06
  15.81
  16.60
  17.43
  18.31
  19.22
  20.18
  21.19
  22.25
  23.36
  24.53
  25.76
  27.05
  28.40
  29.82
  31.31
  32.87
  34.52
  36.24
  38.06
  39.96
  41.96
  44.05
  46.26
  48.57
PV of cash for distribution, $m
 
  -459
  -9
  -30
  -47
  -58
  -66
  -69
  -69
  -66
  -60
  -54
  -46
  -39
  -31
  -25
  -19
  -14
  -10
  -7
  -5
  -3
  -2
  -1
  -1
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  52.6
  49.5
  46.6
  43.8
  41.1
  38.6
  36.2
  34.0
  31.8
  29.8
  28.0
  26.2
  24.6
  23.0
  21.6
  20.2
  18.9
  17.7
  16.6
  15.5
  14.5
  13.6
  12.7
  11.9
  11.1
  10.4
  9.7
  9.0
  8.4
  7.9

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide (TiO2) under the Ti-Pure brand name to deliver whiteness, brightness, opacity, and protection in various applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, PVC window profiles, laminate papers, and coated papers and paperboards used for packaging. The Fluoroproducts segment provides fluoroproducts, including refrigerants, industrial fluoropolymer resins, coatings, and other downstream products under the Teflon, Viton, Krytox, and Nafion brand names. The Chemical Solutions segment offers industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers, and other industries. This segment provides mining solutions; and performance chemicals and intermediates, such as methylamines, glycolic acid, and Vazo free radical initiators. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.

FINANCIAL RATIOS  of  Chemours (CC)

Valuation Ratios
P/E Ratio 1202
Price to Sales 1.6
Price to Book 84.1
Price to Tangible Book
Price to Cash Flow 14.2
Price to Free Cash Flow 32.9
Growth Rates
Sales Growth Rate -5.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -34.9%
Cap. Spend. - 3 Yr. Gr. Rate -5.1%
Financial Strength
Quick Ratio 60
Current Ratio 0
LT Debt to Equity 3529%
Total Debt to Equity 3544%
Interest Coverage 1
Management Effectiveness
Return On Assets -2%
Ret/ On Assets - 3 Yr. Avg. 1.4%
Return On Total Capital 0.2%
Ret/ On T. Cap. - 3 Yr. Avg. 3.2%
Return On Equity 6.2%
Return On Equity - 3 Yr. Avg. 4.4%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 20.6%
Gross Margin - 3 Yr. Avg. 19.5%
EBITDA Margin 8.9%
EBITDA Margin - 3 Yr. Avg. 8.2%
Operating Margin -1.4%
Oper. Margin - 3 Yr. Avg. 1.4%
Pre-Tax Margin -0.2%
Pre-Tax Margin - 3 Yr. Avg. 1.7%
Net Profit Margin 0.1%
Net Profit Margin - 3 Yr. Avg. 1.6%
Effective Tax Rate 163.6%
Eff/ Tax Rate - 3 Yr. Avg. 81%
Payout Ratio 314.3%

CC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CC stock intrinsic value calculation we used $5400 million for the last fiscal year's total revenue generated by Chemours. The default revenue input number comes from 2016 income statement of Chemours. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CC stock valuation model: a) initial revenue growth rate of 10.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 11.8%, whose default value for CC is calculated based on our internal credit rating of Chemours, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Chemours.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CC stock the variable cost ratio is equal to 102.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.5% for Chemours.

Corporate tax rate of 27% is the nominal tax rate for Chemours. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CC are equal to 55.4%.

Life of production assets of 11.1 years is the average useful life of capital assets used in Chemours operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CC is equal to -1.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $100 million for Chemours - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 182.316 million for Chemours is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Chemours at the current share price and the inputted number of shares is $8.4 billion.

RELATED COMPANIES Price Int.Val. Rating
DD E.I. DuPont de 81.18 45.65  sell
MMM 3M 203.53 143.59  sell
HUN Huntsman 25.34 6.48  str.sell
KRO Kronos Worldwi 18.90 0.86  str.sell
SHLM A. Schulman 29.55 10.38  str.sell
OXY Occidental Pet 59.15 7.02  str.sell
HON Honeywell Inte 134.95 126.43  hold
VAL Valspar 112.99 57.13  sell

COMPANY NEWS

▶ Chemours Responds to EPA 2015 Ruling to Regulate HFCs   [Aug-09-17 06:17AM  PR Newswire]
▶ Why This Niche Chemical Market Was Red-Hot in July   [Aug-03-17 02:16PM  Motley Fool]
▶ Chemours posts 2Q profit   [12:47AM  Associated Press]
▶ Chemours Announces Third Quarter Dividend   [Aug-02-17 04:30PM  PR Newswire]
▶ ETFs with exposure to The Chemours Co. : July 24, 2017   [Jul-24-17 02:40PM  Capital Cube]
▶ What Can We Expect for DuPonts Earnings per Share in 2Q17?   [Jul-21-17 09:15AM  Market Realist]
▶ Top Ranked Growth Stocks to Buy for July 20th   [Jul-20-17 11:22AM  Zacks]
▶ Chemours Co: Buy at the High?   [10:31AM  Motley Fool]
▶ ETFs with exposure to The Chemours Co. : July 14, 2017   [Jul-14-17 01:20PM  Capital Cube]
▶ Chemours Co (CC) Stock Is a Growth Monster   [Jul-13-17 06:27AM  InvestorPlace]
▶ Top Ranked Growth Stocks to Buy for July 11th   [Jul-11-17 10:00AM  Zacks]
▶ Top Ranked Value Stocks to Buy for June 29th   [Jun-29-17 07:26AM  Zacks]
▶ A Strong World Economy Lifts Chemical Firms   [Jun-28-17 05:34PM  Zacks]
▶ Top Ranked Value Stocks to Buy for June 27th   [Jun-27-17 11:20AM  Zacks]
▶ Behind Chemours Debt Development since Its Spin-Off   [Jun-26-17 04:40PM  Market Realist]
▶ A Strong Case for Selling Chemours Co.   [08:12AM  Motley Fool]
▶ Top Ranked Growth Stocks to Buy for June 23rd   [Jun-23-17 12:00PM  Zacks]
▶ Top Ranked Momentum Stocks to Buy for June 22nd   [Jun-22-17 10:58AM  Zacks]
▶ These Stocks Have Changed Direction   [Jun-19-17 02:00PM  TheStreet.com]
▶ ETFs with exposure to The Chemours Co. : June 15, 2017   [Jun-15-17 01:26PM  Capital Cube]
▶ 3 Stocks That Put NVIDIA Growth to Shame   [Jun-14-17 11:06AM  Motley Fool]
▶ These Stocks Have Quadrupled in 1 Year   [Jun-13-17 11:15AM  Motley Fool]
▶ Chemours Was Added to the Fortune 500 List   [07:38AM  Market Realist]
▶ Top Ranked Growth Stocks to Buy for June 9th   [Jun-09-17 11:29AM  Zacks]
▶ The Chemours Co. Value Analysis (NYSE:CC) : June 8, 2017   [Jun-08-17 02:08PM  Capital Cube]
▶ Top Ranked Growth Stocks to Buy for June 5th   [Jun-05-17 11:39AM  Zacks]
▶ Top Ranked Growth Stocks to Buy for June 1st   [Jun-01-17 11:41AM  Zacks]
▶ Top Ranked Growth Stocks to Buy for May 31st   [May-31-17 11:35AM  Zacks]
▶ Top Ranked Growth Stocks to Buy for May 26th   [May-26-17 11:58AM  Zacks]
Stock chart of CC Financial statements of CC
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.